CN113521049A - 一种妊娠纹脱模修复方法 - Google Patents
一种妊娠纹脱模修复方法 Download PDFInfo
- Publication number
- CN113521049A CN113521049A CN202110862344.3A CN202110862344A CN113521049A CN 113521049 A CN113521049 A CN 113521049A CN 202110862344 A CN202110862344 A CN 202110862344A CN 113521049 A CN113521049 A CN 113521049A
- Authority
- CN
- China
- Prior art keywords
- skin
- cells
- demolding
- repair
- stretch mark
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008439 repair process Effects 0.000 title claims abstract description 24
- 208000031439 Striae Distensae Diseases 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 230000001737 promoting effect Effects 0.000 claims abstract description 10
- 239000012528 membrane Substances 0.000 claims abstract description 9
- 230000008929 regeneration Effects 0.000 claims abstract description 8
- 238000011069 regeneration method Methods 0.000 claims abstract description 8
- 229930192334 Auxin Natural products 0.000 claims abstract description 7
- 239000002363 auxin Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 7
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000003213 activating effect Effects 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 48
- 210000003491 skin Anatomy 0.000 claims description 38
- 150000002500 ions Chemical class 0.000 claims description 15
- 230000020411 cell activation Effects 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 12
- 210000004927 skin cell Anatomy 0.000 claims description 11
- 230000010261 cell growth Effects 0.000 claims description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 150000001450 anions Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960002916 adapalene Drugs 0.000 claims description 6
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 5
- 108020001507 fusion proteins Proteins 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229960001727 tretinoin Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 abstract description 12
- 230000006798 recombination Effects 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 230000012010 growth Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 108010083687 Ion Pumps Proteins 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- RUXQWZJWMCHCHH-IZZDOVSWSA-N [(e)-1-pyridin-2-ylethylideneamino]urea Chemical compound NC(=O)N\N=C(/C)C1=CC=CC=N1 RUXQWZJWMCHCHH-IZZDOVSWSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 108700018610 polyethylene glycol-recombinant human growth hormone Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及皮肤修复领域,具体为一种妊娠纹脱模修复方法,包括以下步骤:S1、皮膜脱离分层,涂抹适量的药物,一段时间后,使得涂抹部位皮肤与外层皮膜发生分离;S2、激活沉睡的细胞,服用细胞激活能量蛋白,S3、修复受损的细胞,S4、重组缺失的细胞,在皮肤表面涂抹细胞基因生长素,促进缺失的细胞再生,从而重组受损细胞;S5、表层皮肤组织修复,S6、维护治疗,皮肤物理康复、本发明实现了对妊娠纹部位受损皮肤的快速分离修复与重组,可以高效高速的实现对妊娠纹的清除,且本发明相较于现有的激光点阵治疗和仪器(微针、微晶、注射器)等疗法,最为突出的便是不破皮、不流血、不激光、不植皮、不用任何仪器,便可实现对皮肤问题的修复。
Description
技术领域
本发明涉及皮肤修复领域,具体为一种妊娠纹脱模修复方法。
背景技术
妊娠纹的形成主要是由于妊娠期荷尔蒙的影响,加之腹部膨隆使皮肤的弹力纤维与胶原纤维损伤或断裂,腹部皮肤变薄变细,出现一些宽窄不同、长短不一的粉红色或紫红色的波浪状花纹。分娩后,这些花纹会逐渐消失,留下白色或银白色的有光泽的瘢痕线纹,即妊娠纹。妊娠纹主要出现在腹壁上,也可能出现在大腿内外侧、臀部、胸部、后腰部及手臂等处。初产妇最为明显。一旦出现妊娠纹就不会消失,并伴随皮肤松弛、乳房下坠、腹部脂肪堆积,严重影响了妇女产后的体态和身心健康。
专利号CN101172091A提供了能刺激皮肤相关细胞修复、并具持续作用的含重组融合蛋白产品的组成和制备工艺,用以改善皮肤质量、达到美容、除皱、祛斑、美白作用。特别是,本发明提供了人血清白蛋白(HSA)和一种细胞因子多肽(EGF、FGF、KGF、HGH、HGF、PDGF、GCSF、干扰素、IL-11或IGF)利用基因工程技术重组形成的融合蛋白,单独、或复合组成、或与酵母菌发酵产物、或与人血清白蛋白单独或复合组成,还可有各种乳化剂、增稠剂、保湿剂、防腐剂、酵母酵素等组分一起制作成各种、各式的用于改善皮肤质量的产品。
除了妊娠纹,生长纹,肥胖纹都是因为皮肤弹力纤维与胶原纤维损伤或断裂导致的皮肤出现纹路,严重的影响了人们的身心健康,现有技术通常通过食疗,或者在皮肤表面涂抹一些美容产品来消除妊娠纹,而该方式见效慢,且效果有限,为此我们提出了一种妊娠纹脱模修复方法。
发明内容
本发明的目的在于提供一种妊娠纹脱模修复方法,包括以下步骤:
S1、皮膜脱离分层,涂抹适量的药物,一段时间后,使得涂抹部位皮肤与外层皮膜发生分离;
S2、激活沉睡的细胞,服用细胞激活能量蛋白,对皮肤细胞进行处理,促进细胞活化;
S3、修复受损的细胞,通过负离子修复,促进受损的细胞进行自我修复;
S4、重组缺失的细胞,在皮肤表面涂抹细胞基因生长素,促进缺失的细胞再生,从而重组受损细胞;
S5、表层皮肤组织修复,在皮肤表面涂抹生长因子,促进表层皮肤组织再生,从而修复表皮皮肤组织;
S6、维护治疗,皮肤物理康复、提供皮肤细胞生长适宜环境。
优选的:所述步骤1中的药物为维A酸类的。
优选的:所述的中维A酸类包括乐为乳膏,阿达帕林和安素丝中的一个,或为乐为乳膏,阿达帕林和安素丝之间按照不同比例调和的混合物。
优选的:所述的步骤S2中细胞激活能量蛋白的物品为人血清蛋白与皮肤细胞生长因子融合蛋白。
优选的:所述的步骤S3中负离子为带有负电荷的单个粒子和氢离子团。
优选的:所述的步骤S4所述的细胞基因生长素包括粉剂,水剂,长效制剂中的至少一种。
优选的:所述的步骤S6中皮肤细胞生长适宜环境包括,适宜的环境温度,适宜的水分补充等。
与现有技术相比,本发明的有益效果是:
本发明通过S1-S6步骤的操作,实现了对妊娠纹部位受损皮肤的快速分离修复与重组,可以高效高速的实现对妊娠纹的清除,且本发明相较于现有的激光点阵治疗和仪器(微针、微晶、注射器)等疗法,最为突出的便是不破皮、不流血、不激光、不植皮、不用任何仪器,便可实现对皮肤问题的修复。
附图说明
图1为本发明一种妊娠纹脱模修复方法流程示意图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
请参阅图1,图为本发明一种妊娠纹脱模修复方法,包括以下步骤:
S1、皮膜脱离分层,涂抹适量的药物,一段时间后,使得涂抹部位皮肤与外层皮膜发生分离,所述的药物为维A酸类的,所述的中维A酸类包括乐为乳膏,阿达帕林和安素丝中的一个,或为乐为乳膏,阿达帕林和安素丝之间按照不同比例调和的混合物,维A酸分子式为C20H28O2,是体内维生素A的代谢中间产物,主要影响骨的生长和促进上皮细胞增生、分化、角质溶解等代谢作用。用于治疗寻常痤疮、银屑病、鱼鳞病、扁平苔癣、毛发红糠疹、毛囊角化病、鳞状细胞癌及黑色素瘤等疾病;
S2、激活沉睡的细胞,服用含有细胞激活能量蛋白的物品,对皮肤细胞进行处理,促进细胞活化,细胞激活能量蛋白的物品为人血清蛋白与皮肤细胞生长因子融合蛋白,细胞激活能量蛋白,按照细胞线粒体激活黄金组合,配合其他延缓衰老的成分如:细胞能量剂、细胞抗氧化剂、细胞激活剂、维生素、支链氨基酸,辅助加勒比海鲨鱼软骨胶原蛋白搭配而成,服用之后可以显著提高机体的新陈代谢能力、提高免疫机能、抗疲劳能力、改善心脏功能、改善睡眠、促进干细胞生长、提高记忆力及性功能、促进皮肤内源性胶原蛋白及弹力蛋白合成、预防肿瘤的作用细胞激活能量蛋白作为改善机体内环境及干细胞线粒体激活剂,不仅可以作为日常保健品服用,同时有必要在细胞抗衰老治疗之前使用,清除机体毒素及垃圾,为休眠的干细胞APSC多能细胞提供能量使之激活,为新细胞植入提供一个良好的内生长环境;也有必要在细胞抗衰老治疗之后使用,为新植入的鲜活细胞提供大量能量,使鲜活细胞可以快速、长期在体内存活,具有辅助及维持细胞抗衰老效果的重要作用。
S3、修复受损的细胞,通过负离子修复,促进受损的细胞进行自我修复;所述的负离子为带有负电荷的单个粒子和氢离子团,负离子会参与细胞膜离子转运机制;负离子可以增加细胞内供氧;负离子能加速细胞修复功能和再生能力;负离子参与细胞基因的活化和自主修复;负离子调节体液机制;负离子消除白由基;负离子可以增强脑吗啡的分泌;负离子神经调整机制等,在此我们通过回答以下几个大家比较关心的问题,来让各位了解负离子帮助治疗疾病与保健原理,问:负离子以何种方式参与细胞离子膜转运机制的?答:人体细胞膜上有一种称为“离子泵”的东西,它特有益于人的离子进入细胞内,不益于人的离子排出细胞外,“离子泵”的能量不足这项功能就会减弱,人体便会出现疾病状态,而负离子可以提高离子泵的能量恢复其正常运转功能,从而达到治疗疾病的效果,问:负离子怎么样增加细胞供氧?答:氧对人体健康的作用之重要是众所周知的,血液中的血小板能够释放出一种会阻止细胞对氧摄入的物质:“5-羟色胺”,该物质会造成细胞缺氧从而影响我们人体的健康,而当人吸入的负离子数目足够多时,这种物质的释放就会减少甚至停止,也就是说负离子是通过抑制血小板释放5-羟色胺,来提高细胞对氧的摄入从而有利于人体的健康;
S4、重组缺失的细胞,在皮肤表面涂抹细胞基因生长素,促进缺失的细胞再生,从而重组受损细胞,所述的细胞基因生长素包括粉剂,水剂,长效制剂中的至少一种,粉剂是重组人生长激素注射用冻干粉针剂,注射时需以无菌注射用水溶解后,以一次性无菌注射液注射,注射频率为每天一次,水剂是重组人生长激素注射液,大部分为卡式瓶包装,该剂型的生长激素含有符合药典规定的抑菌剂(如苯酚),可多次反复注射,无需溶解,直接以一次性无菌注射器抽取注射,或者使用特殊配套装置(电子笔式注射器)注射,注射频率为每天一次,长效制剂聚乙二醇重组人生长激素注射液,为我国自主研发的长效生长激素制剂,目前已经上市,无需溶解,直接以注射器抽取注射,注射频率为每周一次;
S5、表层皮肤组织修复,在皮肤表面涂抹生长因子,促进表层皮肤组织再生,从而修复表皮皮肤组织,生长因子,是一类调节微生物正常生长代谢所必需,但不能用简单的碳、氮源自行合成的有机物,广义的生长因子除了维生素外,还包括碱基、嘌呤、嘧啶、生物素和烟酸等,有时还包括氨基酸营养缺陷突变株所需要的氨基酸在内;而狭义的生长因子一般仅指维生素,一类通过与特异的、高亲和的细胞膜受体结合,调节细胞生长与其他细胞功能等多效应的多肽类物质,存在于血小板和各种成体与胚胎组织及大多数培养细胞中,对不同种类细胞具有一定的专一性,通常培养细胞的生长需要多种生长因子顺序的协调作用,肿瘤细胞具有不依赖生长因子的自主性生长的特点;其中重组人表皮生长因子是一种小肽,由53个氨基酸残基组成,是类EGF大家族的一个成员,一种多功能的生长因子:在体内体外都对多种组织细胞有强烈的促分裂作用,EGF同应答细胞表面的特异受体结合,(根据《斯诺美-走在生物医学美容最前沿》A10文献记载)一旦结合,便促进受体二聚化并使细胞质位点磷酸化,被激活的受体至少可与5种具有不同信号序列的蛋白结合,进行信号转导,在翻译水平上对蛋白质的合成起调节作用,此外EGF可提高细胞内DNA拓扑异构酶活性,也可促进一些与增殖有关的基因表达,如myc、fos等。
S6、维护治疗,皮肤物理康复、提供皮肤细胞生长适宜环境,是皮肤生长处于适合的温度、湿度等环境下,促进细胞的快速生长,减小治疗周期。
以上内容是结合具体实施方式对本发明作进一步详细说明,不能认定本发明具体实施只局限于这些说明,对于本发明所属技术领域的普通技术人员来说,在不脱离本发明的构思的前提下,还可以做出若干简单的推演或替换,都应当视为属于本发明所提交的权利要求书确定的保护范围。
Claims (7)
1.一种妊娠纹脱模修复方法,其特征在于,包括以下步骤:
S1、皮膜脱离分层,涂抹适量的药物,一段时间后,使得涂抹部位皮肤与外层皮膜发生分离;
S2、激活沉睡的细胞,服用细胞激活能量蛋白,对皮肤细胞进行处理,促进细胞活化;
S3、修复受损的细胞,通过负离子修复,促进受损的细胞进行自我修复;
S4、重组缺失的细胞,在皮肤表面涂抹细胞基因生长素,促进缺失的细胞再生,从而重组受损细胞;
S5、表层皮肤组织修复,在皮肤表面涂抹生长因子,促进表层皮肤组织再生,从而修复表皮皮肤组织;
S6、维护治疗,皮肤物理康复、提供皮肤细胞生长适宜环境。
2.根据权利要求1所述的的一种妊娠纹脱模修复方法,其特征在于:所述步骤1中的药物为维A酸类的。
3.根据权利要求2所述的的一种妊娠纹脱模修复方法,其特征在于:所述的维A酸类包括乐为乳膏,阿达帕林和安素丝中的一个,或为乐为乳膏,阿达帕林和安素丝之间按照不同比例调和的混合物。
4.根据权利要求1所述的的一种妊娠纹脱模修复方法,其特征在于:所述的步骤S2中细胞激活能量蛋白的物品为人血清蛋白与皮肤细胞生长因子融合蛋白。
5.根据权利要求1所述的的一种妊娠纹脱模修复方法,其特征在于:所述的步骤S3中负离子为带有负电荷的单个粒子和氢离子团。
6.根据权利要求1所述的的一种妊娠纹脱模修复方法,其特征在于:所述的步骤S4所述的细胞基因生长素包括粉剂,水剂,长效制剂中的至少一种。
7.根据权利要求1所述的的一种妊娠纹脱模修复方法,其特征在于:所述的步骤S6中皮肤细胞生长适宜环境包括,适宜的环境温度,适宜的水分补充等。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110862344.3A CN113521049A (zh) | 2021-07-29 | 2021-07-29 | 一种妊娠纹脱模修复方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110862344.3A CN113521049A (zh) | 2021-07-29 | 2021-07-29 | 一种妊娠纹脱模修复方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113521049A true CN113521049A (zh) | 2021-10-22 |
Family
ID=78121395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110862344.3A Pending CN113521049A (zh) | 2021-07-29 | 2021-07-29 | 一种妊娠纹脱模修复方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113521049A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080031850A1 (en) * | 2003-12-30 | 2008-02-07 | Augustinus Bader | Tissue Regeneration Method |
CN101172091A (zh) * | 2007-09-25 | 2008-05-07 | 天津溥瀛生物技术有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
CN101249043A (zh) * | 2008-04-03 | 2008-08-27 | 冯来坤 | 人生长激素和人表皮生长因子组合物在美容中的应用 |
CN101732797A (zh) * | 2009-07-07 | 2010-06-16 | 廖植生 | 自助式多功能个人修复护理仪 |
CN105832637A (zh) * | 2016-05-11 | 2016-08-10 | 沈平 | 一种化妆品用纳米负离子功能材料及其制备方法 |
CN108057015A (zh) * | 2018-01-12 | 2018-05-22 | 李忠 | 一种妊娠纹修复油、制备方法及其应用 |
CN108743425A (zh) * | 2018-04-20 | 2018-11-06 | 南通蛇类治疗研究所 | 补充皮肤元素的天然药石润肤霜 |
-
2021
- 2021-07-29 CN CN202110862344.3A patent/CN113521049A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080031850A1 (en) * | 2003-12-30 | 2008-02-07 | Augustinus Bader | Tissue Regeneration Method |
CN101172091A (zh) * | 2007-09-25 | 2008-05-07 | 天津溥瀛生物技术有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
CN101249043A (zh) * | 2008-04-03 | 2008-08-27 | 冯来坤 | 人生长激素和人表皮生长因子组合物在美容中的应用 |
CN101732797A (zh) * | 2009-07-07 | 2010-06-16 | 廖植生 | 自助式多功能个人修复护理仪 |
CN105832637A (zh) * | 2016-05-11 | 2016-08-10 | 沈平 | 一种化妆品用纳米负离子功能材料及其制备方法 |
CN108057015A (zh) * | 2018-01-12 | 2018-05-22 | 李忠 | 一种妊娠纹修复油、制备方法及其应用 |
CN108743425A (zh) * | 2018-04-20 | 2018-11-06 | 南通蛇类治疗研究所 | 补充皮肤元素的天然药石润肤霜 |
Non-Patent Citations (1)
Title |
---|
柳琪林 等: "重组人生长激素促进烧伤病人创面愈合机制初探", 《中华烧伤杂志》, vol. 16, no. 01, pages 22 - 25 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5681561A (en) | Compositions and methods for improving autologous fat grafting | |
RU2280459C2 (ru) | Средство для изменения скорости роста или репродукции клеток, способ его получения, способ стимуляции заживления ран или лечения ожогов, способ коррекции косметического дефекта, способ ингибирования старения кожи и способ стимуляции роста волос | |
JP5735965B2 (ja) | 充填剤および線維芽細胞成長培地を組合せる注射用組成物 | |
US9101538B2 (en) | Injectable amino-acid composition | |
EP2485754A1 (en) | Methods and compositions for skin regeneration | |
CN111110623A (zh) | 自体修复小小针营养液配方 | |
CN101791283B (zh) | 一种可消除妊娠纹和疤痕的化妆品 | |
CN103860449B (zh) | 一种具有祛除妊娠纹功效的护肤制品及其制备方法 | |
CN113679046B (zh) | 促进透明质酸与胶原蛋白相互作用的组合物及其应用 | |
JP2020511548A (ja) | 治療用のボツリヌス神経毒素 | |
KR20100008763A (ko) | 지방조직 유래 다분화능 줄기세포의 배양물 및 그 추출 단백질을 함유한 화장료용 조성물 | |
JPH0543453A (ja) | 創傷治癒促進用局所用徐放性製剤 | |
US20020001625A1 (en) | Growth-promoting agent | |
CN105543161B (zh) | 复合生物活性因子脂质体及其制备方法 | |
CN113521049A (zh) | 一种妊娠纹脱模修复方法 | |
CN103690393A (zh) | 美白抗皱生物蚕丝面膜 | |
CN110840818A (zh) | 一种美容抗衰制剂及其制备方法 | |
CN113713176B (zh) | 一种水凝胶及其制备方法与应用 | |
CN101919789A (zh) | 表皮生长因子与褪黑素合成的美白抗皱修复液 | |
US20040208916A1 (en) | Patch for the transdermal administration of beneficial substances | |
JPH06510292A (ja) | 慢性肝疾患治療剤 | |
JP2002226395A (ja) | 皮膚創傷治癒促進剤 | |
KR102404662B1 (ko) | 활동성이 향상된 손톱 및 발톱 성장 촉진용 마이크로니들 밴드 | |
CN100562306C (zh) | 含角质细胞生长因子-2的生物美容护肤品和重组人角质细胞生长因子-2的制备方法 | |
CN101057823B (zh) | 一种具有抗衰老及美容作用的复合生物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |